Hormone Therapy for Hot Flashes: The Evidence

How well does hormone therapy work?

A Cochrane systematic review (MacLennan 2004) pooled 24 randomized trials of oral estrogen, alone or with a progestogen, covering 3,329 women. Compared with baseline, hormone therapy reduced weekly hot flash frequency by about 75% (95% CI 64.3 to 82.3), a weighted mean difference of −17.92 fewer episodes per week (95% CI −22.86 to −12.99). Symptom severity was also significantly lower on treatment than on placebo (odds ratio 0.13, 95% CI 0.07 to 0.23).

An important nuance: women assigned to placebo in the same trials still reported a 57.7% reduction (95% CI 45.1 to 67.7). Hot flashes fluctuate and respond strongly to expectation, so the meaningful measure is the gap between drug and placebo, not the raw percentage. Even against that large placebo response, hormone therapy came out clearly ahead.

Both groups improved, but hormone therapy reduced hot flash frequency substantially more than placebo. The chart shows the reduction in weekly hot flash frequency from baseline in the pooled Cochrane trials.

What the guidelines say

The Menopause Society (formerly the North American Menopause Society) states in its 2022 hormone therapy position statement that hormone therapy "remains the most effective treatment for vasomotor symptoms" and the genitourinary syndrome of menopause, and has been shown to prevent bone loss and fracture.

The statement frames the decision around timing. For women younger than 60 or within 10 years of their final period, and without contraindications, "the benefit-risk ratio is favorable" for treating bothersome VMS and preventing bone loss. For those who start more than 10 years after menopause or after age 60, the balance "appears less favorable" because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. The society emphasizes individualized care, using the appropriate dose, route, and duration, with periodic reassessment.

Much of the caution around hormone therapy traces to the Women's Health Initiative (WHI), a large randomized trial. Its estrogen-plus-progestin arm (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate), followed a mean of 5.2 years, found more cardiovascular events and breast cancers but fewer colorectal cancers and hip fractures. The absolute differences per 10,000 women-years are small.

Reading benefit and risk together

The WHI hazard ratios sound alarming as percentages, but the absolute effects are modest, on the order of a handful of extra (or fewer) events per 10,000 women each year. Critically, WHI enrolled a mostly older population: only about a third of participants were in their 50s, the age most women actually consider hormone therapy for symptoms. That mismatch is central to the modern "timing" view, in which starting closer to menopause carries a more favorable balance than starting a decade or more later.

A longer-view Cochrane review of long-term hormone therapy (Marjoribanks 2017) reached a compatible bottom line: women with intolerable symptoms may reasonably weigh symptom relief against the small absolute risks of short-term, low-dose therapy, provided they do not have specific contraindications such as elevated cardiovascular, clotting, or certain cancer risks. In short, efficacy is not in serious doubt; the decision hinges on individual risk, age, and timing.

Talking it through with a clinician

Hot flashes and night sweats are the same vasomotor phenomenon, so the efficacy figures here apply to both. Whether hormone therapy is appropriate (and at what dose, route, and duration) depends on personal and family history that only a clinician can weigh. Anyone considering starting, stopping, or changing hormone therapy, or who has new or unusual symptoms, should discuss it with a healthcare professional. Nothing on this page is a diagnosis or a treatment recommendation.

Methodology and limitations

This page draws on a Cochrane meta-analysis of randomized trials for efficacy (MacLennan 2004), The Menopause Society's 2022 position statement for clinical positioning, the Women's Health Initiative principal-results paper (JAMA 2002) for absolute risk figures, and a Cochrane review of long-term hormone therapy (Marjoribanks 2017) for context. Every figure was traced to its source and confirmed.

Limitations: efficacy trials measured hot flash frequency and severity, endpoints with large placebo responses, so drug-versus-placebo differences matter more than raw percentages. WHI risk figures come from one regimen (conjugated equine estrogens plus medroxyprogesterone acetate) in a mostly older population, and do not necessarily generalize to other formulations, routes (e.g., transdermal), doses, or to women starting near menopause. Hazard ratios describe relative risk; absolute differences are small and vary with individual baseline risk. This is general educational information, not medical advice, and not a basis for any treatment decision.

Frequently asked questions

How effective is hormone therapy for hot flashes?

Very. A Cochrane meta-analysis of 24 trials (3,329 women) found hormone therapy reduced weekly hot flash frequency by about 75%, and cut symptom severity as well. The Menopause Society's 2022 statement calls it the most effective treatment for vasomotor symptoms.

Why does placebo also reduce hot flashes so much?

In the same Cochrane trials, placebo cut hot flashes by about 57.7%. Hot flashes fluctuate and respond strongly to expectation, so researchers judge treatments by the gap over placebo. Hormone therapy still clearly outperformed placebo.

How risky is hormone therapy?

In the WHI trial's estrogen-plus-progestin arm, absolute risks rose by roughly 7–8 events per 10,000 women-years each for heart disease, stroke, clots, and breast cancer, while colorectal cancers and hip fractures fell. The absolute numbers are small and depend on age, timing, and personal risk.

Does timing matter for hormone therapy?

According to the Menopause Society, yes. For women under 60 or within 10 years of menopause and without contraindications, the benefit-risk balance is favorable; starting more than 10 years out or after 60 shifts the balance less favorably.

Do the WHI numbers apply to everyone?

Not directly. WHI tested one specific oral regimen in a largely older population, and only about a third of participants were in their 50s. Other formulations, doses, routes, and starting ages may carry different balances, which is why care is individualized.

Is this medical advice?

No. These are verified efficacy and risk figures for general education. Whether hormone therapy is right for you depends on personal history and should be decided with a clinician.

Sources

Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).

1. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978, 75% reduction in weekly hot flush frequency (95% CI 64.3–82.3). PubMed
2. The North American Menopause Society (The Menopause Society). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. PubMed
3. Writing Group for the Women's Health Initiative Investigators (Rossouw JE, et al.). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. Absolute excess per 10,000 person-years: 7 CHD, 8 strokes, 8 PEs, 8 breast cancers; 6 fewer colorectal cancers, 5 fewer hip fractures. PubMed
4. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1):CD004143. Cochrane Library

How to cite this page

Related reading on this site

• Non-hormonal treatments for hot flashes: what works
• Menopause sweating statistics
• How long do hot flashes and night sweats last?
• Can menopause cause sweating?
• Sweat and hormones: the topic hub